A trio of new studies showed that SGLT2 inhibitors and GLP-1 agonists are often not prescribed or accessible to people who could benefit from them.
Receive email when new articles are published onSodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists are often not prescribed or accessible to people who could benefit from them, a trio of new studies suggested.
"There is no question that the cost of these medications is high, yet when issues go beyond coverage and include sociodemographic and racial differences that influence treatment, these major issues need to be evaluated and addressed," said Eckel, professor emeritus of medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Denver, Colorado, and a past president of the AHA.
Individuals with diabetes or hypertension were more likely to be prescribed one of these medications . The rate of annual pharmacy dispensing of SGLT2 inhibitors and GLP-1 RA medications rose during the study period, but there were clear racial and ethnic differences in prescribing. "Our study revealed a significant gap between the recommendations for prescribing SGLT2 inhibitors and the actual prescription rates among patients who could benefit from them," Jung-Im Shin, MD, PhD, with the Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland, told"This could have important implications for patient care and outcomes, as SGLT2 inhibitors have been shown to be effective for heart and kidney protection in...
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1 Agonists and SGLT2 Inhibitors Do Not Increase Autoimmune RiskPatients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease than those prescribed DPP-4 inhibitors.
Read more »
Former JEA CEO found guilty in federal fraud, conspiracy case; former CFO found not guiltyFormer JEA CEO Aaron Zahn was found guilty by a federal jury on Friday of attempting to defraud the city-owned utility.
Read more »
Help Patients Prevent Weight Gain After Stopping GLP-1sCan your patient keep the weight off without the medication? Here are expert-backed ways to help them try.
Read more »
Amid Global GLP-1 Shortages, Doctors Prioritize PatientsSome governments are asking clinicians to reserve prescriptions for those with type 2 diabetes.
Read more »
GLP-1s' Next Target: Male Infertility?Most data on GLP-1 RAs and male fertility come from animal trials or small studies investigating weight loss, but experts say there might be potential here.
Read more »
Gaps are narrowing in Israel-Hamas cease-fire talks, Blinken says during Mideast visitU.S. Secretary of State Antony Blinken says the “gaps are narrowing” in indirect negotiations between Israel and Hamas over another cease-fire and hostage release that the U.S., Egypt and Qatar have spent several weeks trying to broker
Read more »